guest ::
| Home > Publications database > Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. > print |
| Home > Publications database > Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. > print |
| 001 | 290221 | ||
| 005 | 20251018115459.0 | ||
| 024 | 7 | _ | |a 10.1016/j.eururo.2024.04.030 |2 doi |
| 024 | 7 | _ | |a pmid:38749854 |2 pmid |
| 024 | 7 | _ | |a 0302-2838 |2 ISSN |
| 024 | 7 | _ | |a 1421-993X |2 ISSN |
| 024 | 7 | _ | |a 1873-7560 |2 ISSN |
| 024 | 7 | _ | |a altmetric:163372718 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-01039 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Krilaviciute, Agne |0 P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2024 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1734098976_32126 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:C130#LA:C130# / 2024 Dec;86(6):493-500 |
| 520 | _ | _ | |a Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55-60 yr.To identify men at age 45 yr with a low risk of PCa.A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen (PSA) starting in young men (PROBASE).PSA measurements starting at the age of 45 yr.The incidence of PCa within 5 yr was assessed in men with screen-negative baseline PSA <1.5 ng/ml compared with those with PSA 1.5-≤3.0 ng/ml.Of 23301 men who received a first PSA test at age 45 yr, 0.79% had a screen-positive PSA value of ≥3 ng/ml. Among the 89% of men who had a screen-negative baseline PSA value of <1.5 ng/ml, only 0.45% received a positive PSA test ≥3 ng/ml upon retesting after 5 yr. By contrast, for those with a screen-negative baseline PSA value of 1.5-3 ng/ml, 13% surpassed 3 ng/ml upon biennial testing within the next 4 yr. The incidence of PCa in subsequent screening rounds increased with increasing baseline PSA levels, from 0.13 per 1000 person-years for men with initial PSA level of <1.5 ng/ml to 8.0 per 1000 person-years for those with PSA levels of 1.5-3.0 ng/ml. A limitation is a follow-up time of only 5 yr, so far.Men with baseline PSA <1.5 ng/ml at age 45 yr are at a very low risk of PCa over the next 5 yr.The PROBASE study showed that men with baseline prostate-specific antigen (PSA) <1.5 ng/ml at age 45 yr have a very low prostate cancer detection rate over 5 yr and do not need PSA retesting during this time. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Low risk |2 Other |
| 650 | _ | 7 | |a Prostate cancer |2 Other |
| 650 | _ | 7 | |a Prostate-specific antigen |2 Other |
| 650 | _ | 7 | |a Screening |2 Other |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 1 |u dkfz |
| 700 | 1 | _ | |a Seibold, Petra |0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215 |b 2 |u dkfz |
| 700 | 1 | _ | |a de Vrieze, Maxime |0 P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4 |b 3 |u dkfz |
| 700 | 1 | _ | |a Lakes, Jale |b 4 |
| 700 | 1 | _ | |a Radtke, Jan Philipp |b 5 |
| 700 | 1 | _ | |a Kuczyk, Markus |b 6 |
| 700 | 1 | _ | |a Harke, Nina N |b 7 |
| 700 | 1 | _ | |a Debus, Jürgen |0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |b 8 |u dkfz |
| 700 | 1 | _ | |a Fink, Christoph |0 P:(DE-He78)1d10d985d4c4e83e29dbbee2d03149d6 |b 9 |u dkfz |
| 700 | 1 | _ | |a Herkommer, Kathleen |b 10 |
| 700 | 1 | _ | |a Gschwend, Jürgen E |b 11 |
| 700 | 1 | _ | |a Meissner, Valentin H |b 12 |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 13 |u dkfz |
| 700 | 1 | _ | |a Kristiansen, Glen |b 14 |
| 700 | 1 | _ | |a Hadaschik, Boris |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Arsov, Christian |b 16 |
| 700 | 1 | _ | |a Schimmöller, Lars |b 17 |
| 700 | 1 | _ | |a Antoch, Gerald |b 18 |
| 700 | 1 | _ | |a Giesel, Frederik L |b 19 |
| 700 | 1 | _ | |a Makowski, Marcus |b 20 |
| 700 | 1 | _ | |a Wacker, Frank |b 21 |
| 700 | 1 | _ | |a Schlemmer, Heinz-Peter |0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |b 22 |u dkfz |
| 700 | 1 | _ | |a Becker, Nikolaus |0 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab |b 23 |e Last author |u dkfz |
| 700 | 1 | _ | |a Albers, Peter |0 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578 |b 24 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.eururo.2024.04.030 |g p. S0302283824023583 |0 PERI:(DE-600)1482253-2 |n 6 |p 493-500 |t European urology |v 86 |y 2024 |x 0302-2838 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/290221/files/1-s2.0-S0302283824023583-main.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/290221/files/1-s2.0-S0302283824023583-main.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:290221 |p VDB |p OpenAPC |p openCost |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)1d10d985d4c4e83e29dbbee2d03149d6 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 23 |6 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR UROL : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 20 |0 StatID:(DE-HGF)9920 |2 StatID |b EUR UROL : 2022 |d 2023-10-21 |
| 915 | p | c | |a APC keys set |2 APC |0 PC:(DE-HGF)0000 |
| 915 | p | c | |a Local Funding |2 APC |0 PC:(DE-HGF)0001 |
| 915 | p | c | |a DFG OA Publikationskosten |2 APC |0 PC:(DE-HGF)0002 |
| 915 | p | c | |a DEAL: Elsevier 09/01/2023 |2 APC |0 PC:(DE-HGF)0125 |
| 920 | 2 | _ | |0 I:(DE-He78)C130-20160331 |k C130 |l Personalisierte Früherkennung des Prostatakarzinoms |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C130-20160331 |k C130 |l Personalisierte Früherkennung des Prostatakarzinoms |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 4 |
| 920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l E010 Radiologie |x 5 |
| 920 | 0 | _ | |0 I:(DE-He78)C130-20160331 |k C130 |l Personalisierte Früherkennung des Prostatakarzinoms |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C130-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E050-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E010-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a APC |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|